Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy

    ... analysis, adverse cytogenetics , excess of blasts at the initiation of LEN, and the type of failure (classified as ...

    Research Article last updated 02/21/2017 - 9:43am.

  2. Allogeneic stem cell transplantation in myelodysplastic syndromes: does pretransplant clonal burden matter?

    ... Although patients who undergo alloSCT with excess blasts have poorer outcomes than those transplanted with fewer blasts, the effect of clone size in patients with MDS without increased ...

    Research Article last updated 04/29/2016 - 10:22am.

  3. Are Myelodysplastic Syndromes Underdiagnosed in Poland? A Report by the Polish Adult Leukaemia Group

    ... with MDS and acute myeloid leukaemia (AML) with 20-29% blasts were enrolled. Data collection was conducted for strictly predefined ...

    Research Article last updated 11/02/2016 - 10:17am.

  4. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

    ... 53 (46%) had bone marrow blast clearance (<5% blasts ). Response rates were higher among patients with an unfavorable-risk ...

    Research Article last updated 01/26/2017 - 10:07am.

  5. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

    ... in patients with myelodysplastic syndromes with excess blasts after failure of azacitidine or decitabine ... with diagnosis of refractory anaemia with excess blasts (RAEB)-1, RAEB-2, RAEB-t, or chronic myelomonocytic leukaemia based on ...

    Research Article last updated 06/07/2016 - 11:10am.

  6. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy

    ... with refractory anemia with excess blasts -1, -2, or, -t myelodysplastic syndromes (MDS) following ... addition, 15 patients achieved stabilization of bone marrow blasts. One patient with a complete bone marrow response also achieved a ...

    Research Article last updated 05/22/2014 - 10:23am.

  7. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes

    ... to patients with refractory anaemia with excess blasts (RAEB). In 2025 HMA-treated patients, median survival was 15 months ...

    Research Article last updated 10/06/2016 - 11:34am.

  8. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

    ... 20%, RAEB-2 in 54%, and RAEB-t (AML with 21%-30% marrow blasts ) in 22%. Cytogenetic risk was good in 31%, intermediate in 17%, and ... arabinoside treatment (P = .009), bone marrow blasts > 15% (P = .004), and abnormal karyotype (P = .03) independently ...

    Research Article last updated 07/28/2014 - 8:53am.

  9. The Myelodysplastic Syndromes (MDS): A personal recollection of four decades of classification and prognostic scoring systems.

    ... namely refractory anemia with excess blasts (RAEB) and chronic myelomonocytic leukemia (CMML). Subsequent ... of the degrees of morphologic dysplasia and percentage of blasts have enhanced the classification. Several prognostic scoring systems ...

    Research Article last updated 05/14/2013 - 2:59pm.

  10. Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine.

    ... definition of acute myeloid leukemia (AML) to ≥ 20% blasts , the International Working Group (IWG) response criteria for ... with myelodysplastic syndrome (MDS) with baseline marrow blasts ≥ 20% and < 30% (RAEB-t group) and < 20% (MDS group) were compared. ...

    Research Article last updated 06/28/2013 - 1:20pm.